Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 3:10:900068.
doi: 10.3389/fped.2022.900068. eCollection 2022.

Light protection of parenteral nutrition, cholestasis, and other prematurity-related morbidities in premature infants

Christie Clauss  1 , Valentyna Tack  2 , Maria Macchiarulo  3 , Meredith Akerman  4 , Gladys El-Chaar  1   5 , Nazeeh Hanna  6 , Caterina Tiozzo  6
Affiliations

Light protection of parenteral nutrition, cholestasis, and other prematurity-related morbidities in premature infants

Christie Clauss et al. Front Pediatr. .

Abstract

Introduction: Parenteral Nutrition (PN) can lead to intestinal failure associated liver disease (IFALD). There are no human studies to date studying specifically the benefits of light-protection on neonatal IFALD. Recently, the European Medicines Agency and the American Society for Parenteral and Enteral Nutrition (ASPEN) both recommended full light protection of PN to reduce the risk of adverse clinical outcomes.

Objective: The primary objective of this study was to evaluate the impact of light-protecting PN on the incidence of cholestasis and peak direct bilirubin levels in premature infants.

Study design: Retrospective chart review of preterm infants requiring PN for a minimum of 2 weeks with or without light-protection. After light protection of the PN solution, primary outcomes (including cholestasis and direct bilirubin levels) of both groups were compared. Secondary outcomes include evaluation of bronchopulmonary dysplasia (BPD), necrotizing enterocolitis (NEC), retinopathy of prematurity (ROP), sepsis and mortality.

Results: A total of 50 preterm infants <37 weeks gestation were included, 25 infants in each group. There was a statistically significant decrease in the rate of cholestasis (12 vs. 3, p = 0.005), median peak direct bilirubin levels (1.7 vs. 0.9 mg/dL, p = 0.02) and total bilirubin levels (4.1 vs. 3.4, p = 0.05) in the light-protection group compared to no light-protection group. There was a decrease in the incidence of severe BPD (with an increase of mild BPD, resulting in the same overall BPD rate) in the light-protection compared to no light-protection group (7 vs. 15, p = 0.0223). There was no difference in NEC, ROP, sepsis or mortality.

Conclusion: Our study supports that the practice of light-protecting PN may reduce the incidence of IFALD in premature infants. Moreover, there was a trend toward decreased incidence of severe BPD in the light-protection group. Further light protection studies are needed to confirm these findings.

Keywords: bronchopulmonary dysplasia; cholestasis; direct hyperbilirubinemia; intestinal failure-associated liver disease; light protection; parenteral nutrition; premature infants.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Inclusion and exclusion criteria flow chart.
Figure 2
Figure 2
Population flow chart.
Figure 3
Figure 3
Total and direct bilirubin levels before and after light protection at different time points. (A) Median direct and total bilirubin levels at day of life (DOL) 0 were similar in both groups; (B) Median direct and total bilirubin levels at DOL 14 were significantly lower in the light protection group compared to the no light protection group; (C) Median peak direct bilirubin was significantly lower in the light protection group with no significant difference in median peak total bilirubin levels; and (D) Serum direct and total bilirubin trends across time in the two groups; of note bilirubin trends in both groups started to differentiate after 7 days of PN. DOL, Day of life.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Nutritional interventions to prevent retinopathy of prematurity.
    Hellström A, Kermorvant-Duchemin E, Johnson M, Sáenz de Pipaón M, Smith LE, Hård AL; ESPR Nutrition council members. Hellström A, et al. Pediatr Res. 2024 Sep;96(4):905-911. doi: 10.1038/s41390-024-03208-1. Epub 2024 Apr 29. Pediatr Res. 2024. PMID: 38684884 Free PMC article. Review.

References

    1. Greer FR. Feeding the premature infant in the 20th century. J Nutr. (2001) 131:426S−30S. 10.1093/jn/131.2.426S - DOI - PubMed
    1. Lauriti G, Zani A, Aufieri R, Cananzi M, Chiesa PL, Eaton S, et al. . Incidence, prevention, and treatment of parenteral nutrition-associated cholestasis and intestinal failure-associated liver disease in infants and children: a systematic review. JPEN J Parenter Enteral Nutr. (2014) 38:70–85. 10.1177/0148607113496280 - DOI - PubMed
    1. Zambrano E, El-Hennawy M, Ehrenkranz RA, Zelterman D, Reyes-Mugica M. Total parenteral nutrition induced liver pathology: an autopsy series of 24 newborn cases. Pediatr Dev Pathol. (2004) 7:425–32. 10.1007/s10024-001-0154-7 - DOI - PubMed
    1. Wales PW, Allen N, Worthington P, George D, Compher C, American Society for P et al. . ASPEN clinical guidelines: support of pediatric patients with intestinal failure at risk of parenteral nutrition-associated liver disease JPEN J Parenter Enteral Nutr. (2014) 38:538–57. 10.1177/0148607114527772 - DOI - PubMed
    1. Hoff DS, Michaelson AS. Effects of light exposure on total parenteral nutrition and its implications in the neonatal population. J Pediatr Pharmacol Ther. (2009) 14:132–43. 10.5863/1551-6776-14.3.132 - DOI - PMC - PubMed

LinkOut - more resources